CaRi-Heart Is a Coronary Inflammation AI Imaging Technology
CaRi-Heart is a coronary inflammation AI imaging technology now FDA-authorized, turning routine heart CT scans into a personalized risk score.
Photo source:
CaRi-Heart
CaRi-Heart Is a Coronary Inflammation AI Imaging Technology
Nearly half of all first heart attacks happen
to people who were told they were low risk. That gap between what standard
testing sees and what is actually happening inside a coronary artery is the
problem Caristo Diagnostics built its technology to close. The company, founded
on more than a decade of research originating at the University of Oxford, has
developed CaRi-Heart, a coronary inflammation AI imaging technology that reads
routine cardiac CT scans for signs that conventional analysis misses.
The company recently reached a major regulatory
milestone in the United States, where CaRi-Heart became the first and only
technology authorized by the FDA to quantify coronary inflammation from a
routine coronary CT angiography scan. According to Caristo, the authorization
was granted through the FDA's De Novo pathway, a route reserved for novel
medical devices that have no direct prior equivalent already on the market. The
technology was already in clinical use in the UK, Europe, and Australia before this
US authorization.
How CaRi-Heart Works
CaRi-Heart analyzes the same coronary CT
angiography scan a patient would already receive, without requiring any
additional imaging or invasive procedure. Its core measurement, the FAI-Score,
quantifies inflammation by examining subtle changes in the fat tissue that
surrounds the coronary arteries, known as perivascular adipose tissue.
According to Caristo, active inflammation in an artery wall alters the
composition of this nearby fat in a measurable way, which the CaRi-Heart
software detects and scores.
Hospitals send Caristo a de-identified version
of the CT scan through a secure, cloud-based system, and the analysis is
generated and verified before being returned to the requesting clinician,
typically within 48 hours. Alongside the inflammation measurement, the
platform's CaRi-Plaque component characterizes the coronary plaque visible in
the same scan, and the two results are combined into an individualized
CaRi-Heart Risk Score estimating a patient's future cardiovascular risk. The
entire process works with most existing scanner models and hospital imaging
systems, so it does not require new hardware to adopt.
Exploring the Practical Benefits of CaRi-Heart
For clinicians, the practical value lies in
what standard CT scans alone tend to miss. A patient can show no significant
narrowing or blockage on a routine angiogram and still be at meaningful risk,
because inflammation can be present and active before it produces any visible
obstruction. CaRi-Heart is designed to surface that hidden signal, giving
physicians information they would not otherwise have from the same scan.
The resulting risk score gives clinicians a
more individualized basis for decisions that are otherwise guided largely by
population-level risk calculators. A patient with elevated inflammation but no
visible blockage might be moved toward closer monitoring or earlier preventive
treatment, while a patient with low inflammation might be reassured that
further intervention is not immediately necessary. Because the underlying scan
is one many patients already undergo for chest pain or suspected coronary disease,
the added insight comes without asking a patient to return for another
appointment or procedure.
Unique Angle: A Body of Clinical Evidence Behind the Score
CaRi-Heart's FAI-Score is not a newly proposed
idea introduced alongside the product; it is built on published, peer-reviewed
research examining how perivascular fat attenuation relates to cardiovascular
outcomes, including work published in The Lancet. Caristo has also drawn on the
Oxford Risk Factors and Non-invasive Imaging study, a research program that has
tracked cardiovascular imaging and outcomes data across a large international
patient population, to support the technology's validation.
Before this year's FDA authorization,
CaRi-Heart had already progressed through multiple regulatory approvals in
other regions, and its companion product, CaRi-Plaque, had separately received
its own FDA clearance for plaque analysis. Caristo has stated it will begin
building commercial infrastructure to bring CaRi-Heart to physicians across the
United States, expanding a rollout that already reaches hospitals and clinics
in several other countries.
Industry Context
Cardiovascular imaging has advanced
considerably in recent years, with CT angiography increasingly used as a
first-line tool to investigate suspected coronary artery disease. Most of that
progress has focused on visualizing plaque and blockages more precisely, since
narrowed arteries are the most direct and visible sign of disease.
Inflammation, by contrast, has been harder to measure directly in a living
patient without an invasive procedure, which is part of why it has remained a
less standardized part of routine cardiac risk assessment.
Coronary inflammation AI imaging is still a
young category within cardiology, and CaRi-Heart's authorization establishes a
new precedent rather than joining an already-crowded field. That also means
open questions remain: how quickly hospitals adopt an additional analysis step
into existing workflows, whether insurers broadly reimburse for it beyond the
initial procedural codes now in place, and how the technology performs across
the full diversity of patients and scanner types it will encounter as use expands.
Those answers will come only as real-world adoption grows beyond the patient
populations studied so far.
You have exceeded your free limits for viewing our premium content
Please subscribe to have unlimited access to our innovations.
Get The Latest In Innovation
Join Our Newsletter
Where bold ideas find bold readers.
